Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells.

Molecules (Basel, Switzerland) - 15 Sept 2016

Zhang Xiao-Yu, Zhang Yun-Kai, Wang Yi-Jun, Gupta Pranav, Zeng Leli, Xu Megan, Wang Xiu-Qi, Yang Dong-Hua, Chen Zhe-Sheng

Abstract excerpt

In recent years, tyrosine kinase inhibitors (TKIs) have been shown capable of inhibiting the ATP-binding cassette (ABC) transporter-mediated multidrug resistance (MDR). In this study, we determine whether osimertinib, a novel selective, irreversible EGFR (epidermal growth factor receptor) TKI, could reverse ABC transporter-mediated MDR. The results showed that, at non-toxic concentrations, osimertinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Neoplasms

Share to Piperazines

Source

Open in PubMed Open full text

Identifiers

PMID: 27649127
DOI: 10.3390/molecules21091236
PMCID: PMC6273565

Genes

ABCB1
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells.PMID 27649127Read ↗

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.Semantic proximity Read ↗

Interaction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter ProteinsSemantic proximity Read ↗

ABC Transporter Inhibitors in Reversing Multidrug Resistance to ChemotherapySemantic proximity Read ↗

PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo studySemantic proximity Read ↗

Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivoSemantic proximity Read ↗

Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug ResistanceSemantic proximity Read ↗

Bufalin reverses ABCB1-mediated drug resistance in colorectal cancerSemantic proximity Read ↗

Investigational ABC transporter inhibitorsSemantic proximity Read ↗

Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.Semantic proximity Read ↗

Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivoSemantic proximity Read ↗

Saracatinib (AZD0530) is a potent modulator of ABCB1‐mediated multidrug resistance<i>in vitro</i>and<i>in vivo</i>Semantic proximity Read ↗

Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.